Blood grown from stem cells
August 19, 2008 — dre12
Vials of human blood have been grown from embryonic stem cells for the first time, in research that promises to provide an almost limitless supply suitable for transfusion into any patient.
The achievement by American scientists could lead to clinical trials of the artificially produced blood within two years, and ultimately to an alternative to donations that would transform medicine.
If such blood were made from stem cells of the O- blood type, which is compatible with every blood group but is often in short supply, it could be given safely to anybody who needs a transfusion.
Supplies of synthetically made O- blood could be kept for emergency situations in which there is insufficient time to check a person’s blood group, such as following a train crash or terrorist attack. It would be particularly useful to military doctors treating battlefield trauma injuries.
Stem-cell derived blood would also eliminate the risk of transmitting the pathogens that cause HIV and Creutzfeld Jakob Disease (CJD) through transfusions, as it could not originate from people who carry these infectious agents.
Scientists behind the advance said that it had huge therapeutic potential, and could easily become the first application of embryonic stem cell research to enter widespread clinical use.
“Limitations in the supply of blood can have potentially life-threatening consequences for patients with massive blood loss,” said Robert Lanza, of Advanced Cell Technology (ACT) in Massachusetts, who led the experiments.
“Embryonic stem cells represent a new source of cells that can be propegated and expanded indefinitely, providing a potentially inexhaustible source of red blood cells for human therapy. The identification of a stem cell line with O- blood type would permit the production of compatible ‘universal donor’ blood.”
The work also has more immediate clinical promise that efforts to turn embryonic stem cells into other types of tissue, for treating conditions such as diabetes and Parkinson’s.
One of the biggest safety hurdles that must be cleared before stem cell therapies enter clinical trials is the risk of uncontrolled cell growth causing cancer. Red blood cells, however, do not have nuclei that carry the genetic material that goes wrong in cancer, and thus should not present this danger.
“This could be one of the biggest breaks for the early clinical application of embryonic stem cells,” Dr Lanza said. “There is still work to be done, but we could certainly be studying these cells clinically within the next year or two.”
While a few red blood cells have been created from embryonic stem cells before, the ACT team is the first to mass-produce them on the scale that would be required for medical use. The scientists grew between 10 billion and 100 billion red cells from just six wells of stem cells…
Popularity: 31% [?]
(Sponsor Link: assetant.co.za)

Stumble it!




